TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an announcement.
Botanix Pharmaceuticals Limited has issued 200,000 new fully paid ordinary shares following the exercise of unquoted options. This move, compliant with the Corporations Act, allows the shares to be traded immediately, enhancing the company’s market liquidity and potentially attracting more investors.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in innovative treatments for skin conditions. The company has received FDA approval for Sofdra™, a novel treatment for primary axillary hyperhidrosis, marking it as the first new chemical entity approved for this condition.
Average Trading Volume: 15,090,331
Technical Sentiment Signal: Sell
Current Market Cap: A$284.4M
See more data about BOT stock on TipRanks’ Stock Analysis page.